US Patent 12,409,176: Scope, Claim Architecture, and US Landscape
What is the core invention claim in US 12,409,176?
US 12,409,176 claims a method of treating acute depression in a bipolar-disorder depressive episode using a specific chemical entity identified only as “Compound of Formula I” in the form of a tosylate salt, dosed once daily by oral tablet or capsule, at a dose range equivalent to 1 to 60 mg free base, with a therapeutically effective amount and a pharmaceutically acceptable diluent or carrier. The claim set then narrows and conditions that method across multiple dependent dimensions: episode type, combination therapy with NMDA-targeted agents, monotherapy, timing of response, and safety-risk exclusions/limitations.
The independent claim is claim 1; claims 2 through 11 add definitional and limiting features.
What exactly is claimed in Claim 1 (independent claim)?
Claim 1 recites a single, integrated treatment method with the following required elements:
-
Indication / clinical state
- Treating acute depression
- Where the acute depression is a depressive episode associated with bipolar disorder
-
Therapeutic agent
- Administering a therapeutically effective amount of Compound of Formula I
- The compound must be the tosylate salt form
-
Route and regimen
- Once daily administration
- Oral administration
- In the form of a tablet or capsule
-
Dosage form strength and dose range
- Unit dosage contains the compound as tosylate salt
- Amount is equivalent to 1 to 60 mg of free base
-
Formulation basics
- Unit dosage comprises the compound plus a pharmaceutically acceptable diluent or carrier
-
Overall treatment goal framing
- Claim 1 also contains limitations that feed later dependent claims (e.g., acute response and specific risk constraints via claim 8)
This is an indication-and-regimen-constrained method-of-use claim. It ties infringement to (a) having a bipolar depressive episode that is “acute depression” under the claim language, (b) using the tosylate salt of the specific Formula I compound, and (c) giving once-daily oral dosing in the stated free-base equivalent range.
How do the dependent claims narrow scope?
What episode subtypes are explicitly covered (Claim 2 and Claim 9)?
- Claim 2: The depressive episode is selected from:
- acute major depressive episode
- acute short-duration depressive episode
- acute recurrent brief depressive episode
- Claim 9: The depressive episode is an acute major depressive episode
Together, these claims define “acute depression associated with bipolar disorder” at the sub-episode level and ensure that major depressive presentations within bipolar depression are squarely within scope.
Does the patent cover NMDA combination regimens (Claims 3 and 4)?
- Claim 3: The method further comprises concurrent administration of an NMDA receptor antagonist
- Claim 4: The method further comprises concurrent administration of an NMDA receptor allosteric modulator
These claims expand the protected treatment space to include combination therapy scenarios where the Formula I tosylate is used alongside NMDA-directed agents. They are not alternative independent inventions; they are dependent add-ons to the Claim 1 structure.
What performance and timing outcomes are claimed (Claims 5, 10, 11)?
- Claim 5: The method “provides the patient with an acute response to treatment”
- Claim 10: The depression is alleviated within one week of treatment
- Claim 11: The patient shows an acute response within less than 2 weeks of treatment
These are clinically oriented outcome limitations. They create additional infringement hooks tied to observed response timelines. In practice, this type of limitation can become evidentiary in disputes (trial endpoints, responder definitions, time-to-response metrics), but in claim scope terms they are explicit constraints.
What patient selection and prior-treatment framing is covered (Claim 6)?
- Claim 6: The patient
- has not responded
- or has not responded adequately
- or suffers undesirable side effects from another antidepressant agent
This is a “non-responder / inadequate responder / intolerant” treatment selection limitation, narrowing the method to a specific patient segment.
Is monotherapy required or optional (Claim 7)?
- Claim 7: The compound is administered as monotherapy
This both (i) offers a clear infringement path for single-agent use, and (ii) potentially positions combination regimens (Claims 3 and 4) as dependent add-ons rather than mutually exclusive in all fact patterns. At minimum, Claim 7 identifies a protected single-agent method configuration.
What safety exclusions narrow dosing risk windows (Claim 8)?
- Claim 8 states that the method:
- does not put the patient at risk for
- sedation
- dissociation
- abuse or misuse
- suicidal ideation
- or does not result in hypertension within four hours after administration
This claim is written as a risk limitation tied to early-onset safety. It is also notable that the limitation is time-bound for hypertension (within 4 hours) and categorical for other risks.
What is the practical scope perimeter if you map Claim 1 to infringement variables?
Claim scope is governed by six “must-meet” variables in Claim 1 and additional dependent filters.
Must-meet variables (Claim 1)
- Target condition: acute depression in a bipolar disorder depressive episode
- Drug identity: “Compound of Formula I” (structure not reproduced in the text provided here)
- Salt form: tosylate salt
- Dose strength equivalence: 1 to 60 mg free base equivalent
- Regimen: once daily
- Route: oral, tablet or capsule
Common add-on scope vectors (dependent claims)
- Episode subtype: acute major / short-duration / recurrent brief (Claims 2 and 9)
- Combination therapy: NMDA antagonist or NMDA allosteric modulator (Claims 3 and 4)
- Treatment response: acute response, alleviation within 1 week, acute response under 2 weeks (Claims 5, 10, 11)
- Patient selection: prior antidepressant non-response or intolerance (Claim 6)
- Treatment mode: monotherapy (Claim 7)
- Safety/risk constraints including early hypertension (Claim 8)
How does the claim set position itself versus typical depression IP?
US method-of-use claims in depression often compete across four axes: (a) indication, (b) patient population, (c) dosing regimen and formulation, and (d) response endpoint framing. This claim set stacks all four:
- Indication is constrained to acute bipolar depressive episodes
- Patient selection is constrained to prior antidepressant non-response or intolerance (Claim 6)
- Dosing regimen is constrained to once-daily oral tablet/capsule, with a specific free-base equivalent range (Claim 1)
- Response is constrained to “acute response” and explicit timing thresholds (Claims 5, 10, 11)
- Safety is constrained through specific prohibited or risk-framed outcomes (Claim 8)
- Salt form is explicitly required (tosylate)
From a landscape standpoint, those stacked elements can reduce “design-around by formulation/dosing” if an authorized competitor tries to avoid the exact salt form, dose range, or dosing frequency.
What design-arounds are implicitly threatened by this claim language?
Even without the chemical structure, the claim text itself reveals design-around pressure points:
-
Salt form
- Claim requires the compound “in the form of the tosylate salt.”
- An alternative salt form (if used and still equivalent pharmacologically) can be an immediate non-infringement argument on salt identity for a method-of-use claim requiring that specific salt.
-
Dose frequency
- Claim 1 requires once daily administration.
- Twice-daily or other schedules could be outside the literal scope of Claim 1, unless doctrine of equivalents or claim interpretation expands “once daily” in a way that a court would accept.
-
Route and unit dosage format
- Only oral tablet or capsule is stated.
- Alternative routes (e.g., injection) or other oral formats not conforming to “tablet or capsule” may avoid literal infringement.
-
Dose range
- Claim 1 uses a strict range: 1 to 60 mg free base equivalent.
- Dosing below 1 mg or above 60 mg could avoid the literal range for Claim 1.
-
Episode definition and patient selection
- Claims target “acute depression associated with bipolar disorder” with further explicit episode subtype selection (Claim 2 and Claim 9).
- Claim 6 adds a prior-treatment non-response or intolerance requirement.
-
Timing outcomes and safety constraints
- Claims 10 and 11 tie to “alleviated within one week” and “acute response within less than 2 weeks.”
- Claim 8 frames safety exclusions including hypertension within 4 hours.
What is missing to fully complete a US patent landscape map (and how the scope analysis still informs it)?
A complete “patent landscape” requires the actual patent document metadata and related family members: assignee(s), filing and priority dates, expiration/term adjustments, claim construction in office actions or litigation, and which earlier patents disclose Formula I, its tosylate, and bipolar depression methods. The prompt provides only the claim text subset. With only that, the landscape can be described only at the level of scope mechanics (what must be used to infringe) and where overlap likely exists conceptually (salt form, dosing regimen, bipolar acute depression, NMDA combinations), not by citing specific US application/publication numbers, expiration dates, or competitor dossiers.
Accordingly, the landscape section below focuses on scope-driven overlap rather than enumerating each competitor’s US patents and Orange Book listings.
Landscape hotspots created by this claim set (scope-driven overlap map)
Hotspot 1: “Compound of Formula I” and tosylate salt
- Any competitor developing a version of Formula I that does not use the tosylate salt can attempt to move outside a literal method claim that requires the tosylate form.
- If competitors use tosylate specifically, this claim set creates a direct pathway to method infringement.
Hotspot 2: Bipolar depression “acute” sub-episode framing
- Many depression programs pursue major depressive disorder (MDD) broadly.
- This claim set is narrower: bipolar disorder depressive episodes labeled as acute and further refined into acute major/short-duration/recurrent brief categories.
Hotspot 3: Once-daily oral dosing and 1 to 60 mg free-base equivalent
- Even with the same drug and indication, changing daily frequency and/or unit dosage amount can be an actionable design-around.
- The “free base equivalent” language increases precision around salt conversion and dosing equivalence.
Hotspot 4: NMDA receptor antagonist/allosteric modulator combinations
- This expands vulnerability to combination products, co-therapies, and labeling-directed coadministration claims, depending on how “concurrent” is construed.
Hotspot 5: Response timing endpoints and early safety constraints
- Claims anchored to “within one week” and “less than 2 weeks” target the time-to-benefit profile.
- Claim 8’s safety limitations, especially the “hypertension within four hours” element, can intersect with trial design, PK/PD sampling timing, and adverse event reporting.
How should investors and R&D leaders use this scope for freedom-to-operate screening?
Enforcement risk matrix (literal scope drivers)
A product or protocol is at higher literal risk if it matches more elements of Claim 1 plus dependent claims:
- High risk: Formula I tosylate, once-daily oral tablet/capsule, 1 to 60 mg free-base equivalent, for acute bipolar depressive episode.
- Medium risk: same core drug and indication but different dosing frequency, different salt, or different route.
- Lower risk: different salt form (not tosylate), non-oral route, or dosing outside 1 to 60 mg free-base equivalent.
Litigation evidence focus created by dependent claims
- Trials or real-world protocols documenting:
- responder timing under 2 weeks
- alleviation within one week
- early hypertension occurrence within 4 hours
- risk of sedation/dissociation/abuse/misuse/suicidal ideation
- Combination therapy details:
- which NMDA antagonist or NMDA allosteric modulator is coadministered
- dosing overlap timing that satisfies “concurrent”
Key Takeaways
- US 12,409,176 is a method-of-use patent anchored to a specific compound (Formula I) in tosylate salt form, dosed once daily via oral tablet or capsule, at 1 to 60 mg free-base equivalent, for acute bipolar depressive episodes.
- Dependent claims broaden scope into specific bipolar depressive episode subtypes, NMDA-targeted concurrent combination therapy, monotherapy, and explicit response timing (within 1 week; under 2 weeks).
- The claim text also creates enforceable design-around pressure points around salt form (tosylate), dosing frequency (once daily), dose range (1 to 60 mg free-base equivalent), oral tablet/capsule route, and early safety framing (including hypertension within 4 hours).
- Without the full patent document and family/publication metadata, a full competitor-by-competitor US landscape cannot be enumerated here; the scope-driven hotspots above define where overlap and design-around arguments will concentrate.
FAQs
1. Does the patent claim the drug composition itself or only a treatment method?
It claims a method of treating acute bipolar depression by administering Compound of Formula I as the tosylate salt under specific dosing and formulation conditions.
2. Is tosylate salt required for infringement?
Yes. Claim 1 requires the compound “is in the form of the tosylate salt.”
3. What dosing regimen is required in Claim 1?
Once daily oral administration in tablet or capsule form, with 1 to 60 mg free-base equivalent per unit dosage.
4. Are combination regimens within scope?
Yes. Claims 3 and 4 add concurrent NMDA receptor antagonist or concurrent NMDA receptor allosteric modulator administration.
5. What performance endpoints are explicitly claimed?
Claim 10 requires alleviation within one week, and Claim 11 requires an acute response in less than 2 weeks, plus general “acute response” language in Claim 5.
References
[1] US 12,409,176 (claim text as provided in prompt).
